MedTrace Logo

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

NCT02572765 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-04-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the splenic activation in hypertensive patients, as compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will investigate whether the splenic metabolic activity relates to the expression of circulating inflammatory proteins (high-sensitivity C-reactive protein \[hsCRP\]), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.

Conditions

Interventions

OTHER

PET/CT scan

PET/CT scan

Sponsors & Collaborators

  • Neuromed IRCCS

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2022-12-31
Completion
2023-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572765 on ClinicalTrials.gov